MOH Price Prediction Next Week
Technical Analysis
MOH has shown a bearish trend in recent trading sessions, with the stock closing at $284.60 on February 21, 2025. The stock has experienced significant selling pressure, dropping from previous levels around $400.
News Impact & Fundamental Analysis
- Michael Burry's hedge fund recently added new positions in MOH, indicating potential value opportunity
- Cantor Fitzgerald lowered price target to $356 from $406 but maintains Overweight rating, viewing recent selloff as "harsh"
- Barclays maintains Hold rating with $339 price target
Price Prediction for Next Week Based on technical indicators and recent analyst actions:
Target Scenarios:
- Support level: $280
- Resistance level: $295
- Most likely range: $282-290
The stock is likely to consolidate around current levels with slight upward bias due to:
- Oversold conditions after recent sharp decline
- Strong fundamental backing from analysts despite price target cuts
- Institutional investor interest as evidenced by Burry's position
Trading Recommendation HOLD/NEUTRAL for next week. While the stock appears oversold, wait for clear reversal signals before establishing new long positions. Current price levels ($284.60) suggest limited downside risk but require confirmation of trend reversal for bullish positioning.
Target Entry: $282 (support level) Target Exit: $295 (resistance level)
MOH Similar Chart Price Prediction
The price of MOH is predicted to go up -9.07%, based on the high correlation periods with NSC. The similarity of these two price pattern on the periods is 94.31%.
MOH
NSC
Down: -9.07%Similarity: 94.31%
MOH Revenue Forecast
MOH EPS Forecast
MOH FAQs
What is bull’s view on MOH?
What is bear's view on MOH?
What is MOH revenue forecast for next quarter？
What is MOH eps forecast for next quarter？
MOH Analyst's Forecast
David Macdonald
Truist Securities
Strong Buy
2025-01-06
Price Target
$400 → $370
Upside
+24.03%
Truist lowered the firm's price target on Molina Healthcare to $370 from $400 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as "mixed", with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is key and cash flow generation with broadly attractive financial flexibility are set to provide solid support, while the recent valuation re-rating for several names provides a better setup around risk/reward, the analyst tells investors in a research note.
John Stansel
JP Morgan
Buy → Hold
2024-12-17
Price Target
$378 → $350
Upside
+19.95%
Andrew Mok
Barclays
Hold
2024-10-25
Price Target
$359 → $372
Upside
+14.27%
